TABLE 2.
Number and percent of pill days by medication
| ASM | % of all pill days | % of all cost | #1, n (%) | #2, n (%) | #3, n (%) |
|---|---|---|---|---|---|
| Denominator | 10 626 500 pill days | $20 339 416 for all pills | 22 288 pathways | 6560 pathways with a second‐line ASM | 1665 pathways with a third‐line ASM |
| Levetiracetam | 56% | 20% | 13 111 (59%) | 1114 (17%) | 144 (9%) |
| Gabapentin | 11% | 2% | 2900 (13%) | 1553 (24%) | 295 (18%) |
| Valproate | 8% | 9% | 1641 (7%) | 869 (13%) | 237 (14%) |
| Phenytoin | 6% | 4% | 1549 (7%) | 458 (7%) | 93 (6%) |
| Lamotrigine | 6% | 4% | 824 (4%) | 697 (11%) | 223 (13%) |
| Lacosamide | 3% | 39% | 512 (2%) | 480 (7%) | 145 (9%) |
| Topiramate | 2% | 1% | 492 (2%) | 327 (5%) | 113 (7%) |
| Oxcarbazepine | 2% | 1% | 352 (2%) | 257 (4%) | 106 (6%) |
| Carbamazepine | 1% | 2% | 314 (1%) | 154 (2%) | 58 (3%) |
| Pregabalin | 1% | 7% | 217 (1%) | 326 (5%) | 103 (6%) |
| Phenobarbital | 1% | <1% | 124 (1%) | 33 (1%) | 14 (1%) |
| Zonisamide | 1% | <1% | 107 (<1%) | 124 (2%) | 60 (4%) |
| Primidone | 1% | <1% | 104 (<1%) | 99 (2%) | 28 (2%) |
| Eslicarbazepine | <1% | 4% | 19 (<1%) | 35 (1%) | 26 (2%) |
| Perampanel | <1% | <1% | 5 (<1%) | 1 (<1%) | 4 (<1%) |
| Clobazam | <1% | 2% | 4 (<1%) | 12 (<1%) | 6 (<1%) |
| Ethosuximide | <1% | <1% | 4 (<1%) | 1 (<1%) | — |
| Brivaracetam | <1% | 1% | 3 (<1%) | 15 (<1%) | 4 (<1%) |
| Everolimus | <1% | 2% | 2 (<1%) | 2 (<1%) | 2 (<1%) |
| Tiagabine | <1% | <1% | 2 (<1%) | 1 (<1%) | 1 (<1%) |
| Felbamate | <1% | <1% | 1 (<1%) | 1 (<1%) | 1 (<1%) |
| Rufinamide | <1% | <1% | 1 (<1%) | 1 (<1%) | 1 (<1%) |
| Ezogabine | <1% | <1% | — | — | 1 (<1%) |
Abbreviation: ASM, antiseizure medication.